{"entity":{"id":"cadance-304","kind":"trial","name":"CaDAnCe-304","aka":[],"tldr":"CaDAnCe-304 is the first phase 3 of a protein degrader in leukaemia, pitting BTK destruction against the best available BTK inhibitor.","summary":"CaDAnCe-304, sponsored by BeOne, formerly BeiGene, is the first phase 3 of a protein degrader in leukaemia, pitting BTK destruction against the best available BTK inhibitor in relapsed or refractory chronic lymphocytic leukaemia after a covalent BTK inhibitor. It is an open-label trial of about 500 patients randomised equally to the BTK degrader BGB-16673 or pirtobrutinib, each at 200 mg daily, with progression-free survival by independent review as the primary endpoint, following the CaDAnCe-101 phase 1 in which most of 66 patients responded, and enrolment runs from 2025 to 2027. OnCo links it to chronic lymphocytic leukaemia, protein degradation, BTK as a target, BGB-16673, pirtobrutinib and the bottleneck of acquired resistance. Whether degrading BTK beats inhibiting it in patients whose disease has already escaped one inhibitor is the question it exists to answer.","status":"recruiting","asOf":"2026-09-07","links":[{"label":"Trial design (Blood 2025 abstract)","url":"https://ashpublications.org/blood/article/146/Supplement%201/5691/550156/CaDAnCe-304-a-phase-3-open-label-randomized-study"}],"tags":[],"related":[],"cancers":["cll"],"sections":[],"technologies":["protac-degrader"],"targets":["btk"],"drugs":["bgb-16673","pirtobrutinib"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"phase":"3","setting":"Relapsed/refractory CLL/SLL after a covalent BTK inhibitor: BTK degrader BGB-16673 vs pirtobrutinib","sponsor":"BeOne (BeiGene)","enrolledBasis":"registry","outcomes":[]},"route":"/trials/cadance-304/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-treatment-naive","kind":"cancer","name":"Chronic lymphocytic leukaemia, first treatment","route":"/cancers/cll-treatment-naive/"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"}],"drug":[{"id":"bgb-16673","kind":"drug","name":"BGB-16673","route":"/drugs/bgb-16673/"},{"id":"pirtobrutinib","kind":"drug","name":"Pirtobrutinib","route":"/drugs/pirtobrutinib/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"idea":[{"id":"idea-btk-degrader-frontline","kind":"idea","name":"BTK degraders to pre-empt resistance in frontline CLL","route":"/ideas/idea-btk-degrader-frontline/"}],"bottleneck":[{"id":"b-resistance","kind":"bottleneck","name":"Acquired resistance to every therapy","route":"/bottlenecks/b-resistance/"}],"roadmap":[{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}]}}